Category Archives: Medical School

02-05-2012 01:52 LIVE Open dislocation thumb of IP jnt and bony ligament avulsion of radial collateral ligament (RCL) of MCP jnt*.

Go here to read the rest:
YouTube Medical School LIVE Open dislocation thumb - Video

02-05-2012 02:34 QUIZ Palpations post-op ? How to treat.ANSWER on video*.

Excerpt from:
YouTube Medical School QUIZ Palpations post-op ? How to treat - Video

PITTSBURGH, May 3, 2012 /PRNewswire/ -- Funding for a four-year, $2.6-million research study that could impact how certain mental health conditions are managed in primary care settings has been secured by a University of Pittsburgh School of Medicine professor.

The research study is designed to evaluate the effectiveness of Beating the BluesUS, an online cognitive behavioral therapy program that is sold and supported by U Squared Interactive, LLC. Bruce L. Rollman, M.D., M.P.H., professor of medicine, psychiatry, and Clinical and Translational Science at Pitt's School of Medicine, received funding for the study from the National Institute of Mental Health (NIMH).

"The study findings are likely to impact the way that certain mental health conditions are managed in primary care," said Dr. Rollman. "Online computerized CBT programs such as Beating the BluesUS are new and evolving technologies that can improve patient access to personalized, convenient and effective mental health interventions."

The study will measure the effectiveness of Beating the BluesUS (alone, and in combination with an Internet support group), and compare it to treatment as usual for depression and anxiety within primary care. The research study will involve 700 patients, ages 18 to 75, who will be referred to the trial by physicians at a dozen or more UPMC-affiliated primary care practices located across western Pennsylvania.

"We also hope our study will focus further attention on the emerging field of `e-mental health' by other U.S. investigators," Dr.Rollman said.

CBT is a form of psychotherapy that teaches individuals how to change the way they think in order to improve the way they feel and how they respond to problems. It is a widely used and effective modality for people with anxiety and depression.

Over 80 million Americans suffer from a mood or anxiety disorder at some point in their lives and these conditions are associated with substantial reductions in quality of life and an increase in the use of health services.

"Beating the BluesUS's delivery of computerized CBT has demonstrated proven efficacy," said Neal Ryan, M.D., a professor of Psychiatry at Pitt's School of Medicine and a U Squared Interactive board member. "This is important to the health care of our patients in decreasing barriers to access, providing a cost-effective approach to effective management of depression and anxiety and, for some, being a powerful adjunct to various treatment modalities."

U Squared Interactive, LLC, is a joint venture between the UPMC Insurance Services Division and Ultrasis UK Ltd., a London-based company. Beating the Blues is Ultrasis's flagship product for anxiety and depression in the United Kingdom.

Full details of the study can be found at http://clinicaltrials.gov/ct2/show/study/NCT01482806?term=rollman&rank=1.)

Read the original post:
University of Pittsburgh Medical School Professor Secures Funding for Beating the BluesUS Research Study

Public release date: 2-May-2012 [ | E-mail | Share ]

Contact: Ruthann Richter richter1@stanford.edu 650-725-8047 Stanford University Medical Center

STANFORD, Calif. Dramatic changes are needed in medical student education, including a substantial reduction in the number of traditional lectures, according to a perspective piece to be published May 3 in the New England Journal of Medicine by two Stanford University professors.

Medical education has changed little in the past 100 years despite dramatic changes in the world of medicine, the explosion in biomedical information and the ever-growing complexity of the health-care system. The traditional lecture format persists even as class attendance is plummeting and as many complain that the current system is failing to produce compassionate, well-trained physicians.

"Students are being taught roughly the same way they were taught when the Wright brothers were tinkering at Kitty Hawk," write co-authors Charles Prober, MD, senior associate dean for medical education at the Stanford School of Medicine, and Chip Heath, PhD, professor of organizational behavior at the Stanford Graduate School of Business. (Heath and his brother, Dan, also authored a bestselling book, Made to Stick: Why Some Ideas Survive and Others Die.) In contemplating medical education reform, Prober reached out to Heath because a critical goal of any educational effort is to optimize the retention of lessons to increase their "stickiness."

In their perspective, titled "Lecture halls without lectures," Prober and Heath propose a new approach to teaching to make better use of the fixed amount of educational time available to train doctors.

"That's the vision that we want to chase: education that wrings more value out of the unyielding asset of time," the authors write. "Why would anyone waste precious class time on a lecture?"

Prober also has been working closely with Salman "Sal" Khan, the Silicon Valley-based online learning pioneer whose nonprofit effort, Khan Academy, is widely credited, in the words of Bill Gates, for having "turned the classroom and the world of education on its head." Prober and Heath's perspective piece proposes a Khan Academy-styled "flipped-classroom" model of teaching. Lecture content is packaged in 10- to 15-minute videos that are watched by the students at their own pace and as often as necessary to learn the material. Class time is then freed up for more interactive education, with greater emphasis on patients' clinical stories as a way to increase the relevance of the necessary scientific and medical knowledge.

"Teachers would be able to actually teach, rather than merely make speeches," the authors write.

The core biochemistry class at Stanford medical school was redesigned this year to follow this model. The instructors replaced the lecture-based format with short online videos made available to students. "Class time was used for interactive discussions of clinical vignettes that highlighted the biochemical bases of various diseases," the article said. "Student reviews of the course improved substantially from the previous year, and class attendance increased from 30 to 80 percent, even though class attendance was optional."

See more here:
Stanford professors propose 'lecture-less' medical school classes

MINNEAPOLIS, May 1, 2012 /PRNewswire/ --ProUroCare Medical Inc. (PUMD.OB), provider of proprietary medical imaging products, announced today it has received clearance from the U.S. Food & Drug Administration (FDA) for its ProUroScan prostate mechanical imaging (PMI) system. The approval paves the way for men and their families to receive high-resolution visual documentations as an aid in detecting prostate abnormalities that were previously detected by digital rectal examination (DRE). The ProUroScan system constructs color 2D and 3D "maps" of the prostate in real-time that, when in agreement with a DRE finding, can be permanently stored in electronic records for future analysis and comparison. ProUroCare's patented tactile elasticity imaging technology, which uses a handheld pressure-sensing rectal probe and sophisticated image construction software to produce its prostate maps, represents a new imaging modality distinct from traditional ultrasound imaging.

The company plans to introduce the technology in 2012 to a limited number of top U.S. medical care centers in key major metropolitan markets. With assistance from Minneapolis investment firm Cherry Tree & Associates, LLC, ProUroCare has been actively seeking a strategic corporate partner with a strong sales and in-service support presence in the urologic market to fully commercialize its technology.

"This is a major milestone for the company, for physicians looking for more assurance and documentation in their evaluations and for men eager for more information to assess and make decisions about their prostate health," said Rick Carlson, CEO of ProUroCare Medical. "A color image can go a long way in documenting a person's prostate condition, and this development puts us one step closer to supplementing other screening measures with a helpful, high quality visual aid that can be referred and compared to over time."

As a standard of care, the American Urological Association (AUA) currently recommends that beginning at age 40, men receive a DRE and a prostate specific antigen (PSA) blood test in their yearly physical, yet data from community-based studies suggest the positive predictive values of DRE and PSA combined achieve only a 56 percent predictive value. Furthermore, neither test creates a physical or visual record of the prostate. The ProUroScan system is being introduced as an adjunctive technology to a DRE for physicians to use to further clarify and document abnormalities associated with the prostate gland.

"Having a visual aid of irregularities can be so helpful to physicians and patients, particularly in the area of prostate care where decision-making is often difficult," said Dr. Robert Weiss, a urologic oncologist with the Cancer Institute of New Jersey and a faculty member at Robert Wood Johnson Medical School who used the ProUroScan technology as part of its clinical trial process. "The quality and resolution of the images are excellent, providing an immensely valuable supplement to the DRE, where physicians must rely on a gloved finger to feel for changes in the size and shape of the gland."

The prostate imaging system's FDA 510(k) was first submitted by ProUroCare's development partner Artann Laboratories, Inc. and later processed in accordance with the de novo provisions accounted for in Section 513(f)(2) of the Federal Food, Drug and Cosmetic Act. The FDA filings were supported by data from a 2009 National Institute of Health and National Cancer Institute-supported clinical study of patients evaluated at five leading U.S. medical centers, as well as an earlier study conducted specifically at the Robert Wood Johnson Medical Center in New Brunswick, N.J.

About ProUroCare Medical Inc.

ProUroCare Medical Inc. is a publicly traded company engaged in the business of creating innovative medical imaging products. Based in Minneapolis, Minn., the company's stock trades on the OTCBB market.

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of ProUroCare's future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause ProUroCare's results to differ materially from those expressed or implied by such forward looking statements include, but are not limited to, the ability of ProUroCare to find adequate financing to complete the development of its products; the high level of secured and unsecured debt incurred by ProUroCare; the impact and timing of actions taken by the FDA and other regulatory agencies with respect to ProUroCare's products and business; the dependence by ProUroCare on third parties for the development and manufacture of its products; and other risks and uncertainties detailed from time to time in ProUroCare's filings with the Securities and Exchange Commission including its most recently filed Form 10-K and Form 10-Q. ProUroCare undertakes no duty to update any of these forward-looking statements.

Go here to see the original:
ProUroCare Medical Receives FDA Clearance for ProUroScan Elasticity Imaging System

CLEVELAND, May 1, 2012 /PRNewswire/ --University Hospitals Case Medical Center's Harrington Discovery Institute has announced a grant competition that serves as a nationwide search for physician-scientists seeking support to accelerate their promising drug discoveries into novel treatments for patients. The Harrington Scholar-Innovator grants will create a bold new pathway for these researchers, who are inspired by their patients, to discover and create novel therapies.

Lacking government and investor funding and partnerships with pharmaceutical companies, many researchers have drug discoveries that are unable to advance into clinical development.

Aimed at addressing this critical issue, the UH Harrington Discovery Institute, launched in February, is the not-for-profit academic medical engine of The Harrington Discovery and Development Project: a first-of-its-kind, $250 million initiative that also includes a mission-aligned, for-profit development company. Aligning these entities for the first time at an academic medical center provides a comprehensive model to advance discoveries into development and to create novel drugs and therapies for patient care.

"This is an important step forward for our exciting initiative, which is to create a new model for drug discovery and development in academia," says the Institute's Director, Jonathan Stamler, MD. "Supporting physician-scientists through the Harrington Scholar-Innovator grants in their early research will address the funding and expertise gaps that exist, thereby helping these researchers to move their clinical discoveries forward."

The annual grant competition, run by UH Harrington Discovery Institute, will offer to support the translation of research from laboratory to early development stages. Up to ten physician-scientists each year will be supported with Harrington Scholar-Innovator grants of up to $200,000 over two years. Guiding the selection of the grant winners are seven prominent physician-scientists who have joined the UH Harrington Discovery Institute Scientific Advisory Board.

"Beyond the grant, we will be there every step of the way for entrepreneurial physician-scientists," adds Dr. Stamler, who is also Director of the Institute for Transformative Molecular Medicine at University Hospitals Case Medical Center and Case Western Reserve University School of Medicine. "Physician-scientists will be able to tap into a peer network of innovators and mentors within the UH Harrington Discovery Institute's infrastructure to support their discovery efforts."

The grant application is open to physician-scientists at accredited academic medical centers, research institutions, and universities in the United States. Applicants must have a doctorate in medicine, and must demonstrate exceptional promise as physician-scientists. The grant will recognize the importance of innovation to the mission of the physician-scientist. Applications found at UHHarringtonDiscoveryInstitute.org are due by 5 p.m. ET, August 1, 2012, and recipients will be announced in the spring of 2013 at the UH Harrington Discovery Institute's inaugural scientific symposium.

"The Harrington Scholar-Innovator Grants are game-changers for physician-scientists across the country who face a number of obstacles in advancing their breakthroughs through commercialization," said Andrew Schafer, MD, chairman of medicine at Weill Cornell Medical College in New York and physician-in-chief at New York-Presbyterian Hospital. "UH Harrington Discovery Institute has identified these obstacles funding, time pressures and lack of expert guidance and has created a model specifically designed to reduce, or even eliminate, their effects on therapeutic innovation."

Dr. Stamler concludes, "These grants are intended to ensure that physician-scientists can advance their discoveries and that their careers that are dedicated to furthering the mission: To Heal. To Teach. To Discover. This is University Hospitals Case Medical Center's mission, and mirrors that of major academic medical centers and dedicated physician-scientists throughout the country."

# # #

Originally posted here:
University Hospitals Case Medical Center's Harrington Discovery Institute Launches Grant Program to Accelerate Drug ...